For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
But there are no hard facts, and a Ligand obligation clouds future licensing economics.
Merck turns to China for a molecule against one of biopharma’s most extensively studied antigens.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
